Garland J. Scott 4

What Happened

• Garland J. Scott, a director of Enliven Therapeutics (ELVN), was granted a derivative award on 2026-02-12 covering 1,427 shares. The reported acquisition price is $0.00, so there was no cash paid and no immediate value realized on the Form 4.
• This transaction is an award/grant (derivative) rather than an open-market purchase or sale and is typical of non-employee director compensation.

Key Details

• Transaction date: 2026-02-12; Form 4 filed: 2026-02-17 (timely filed within SEC rules).
• Amount: 1,427 shares (derivative award) at $0.00 recorded; total immediate cash value reported = $0.
• Shares owned after transaction: not specified in the filing.
• Footnote: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting or (ii) the date of the 2027 annual meeting, provided the reporting person remains a non-employee director through the applicable vesting date.
• Transaction type code: A = Award/Grant (derivative).

Context

• This appears to be a standard director equity grant (an option or similar derivative) that vests based on continued service; it does not indicate an exercised option or a sale of shares.
• Such compensation grants are common for board members and are generally routine rather than a direct signal of immediate insider buying or selling.